You are here: Industry Insights > Market News > Venezuela payment to COVAX received after funds blocked - Gavi

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Venezuela payment to COVAX received after funds blocked - Gavi

firstwordpharmaJuly 09, 2021

Tag: GAVI , COVAX , COVID-19

Favorites

A spokesperson for the Gavi vaccine alliance said on Thursday that Venezuela has paid its financial commitments to the COVAX vaccine-sharing facility and will be allocated COVID-19 vaccine doses upon availability, as reported by This is Money.

Venezuela payment to COVAX received after funds blocked - Gavi

President Nicolas Maduro had said he was giving COVAX an "ultimatum" to send doses to the nation or return the money Venezuela had already paid.

In June, Venezuelan officials said several payments to cover the $120 million fee had been made, but the final four payments had been blocked by Swiss bank UBS.

Previous:Two-dose COVID-19 vaccine response works against delta variant, researchers find

Next:Argentina announces COVID-19 vaccine supply deal with Moderna

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Venezuela payment to COVAX received after funds blocked - Gavi | Pharmasources.com

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.

Venezuela payment to COVAX received after funds blocked - Gavi

Related News

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

You may like